• 1. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Rhoeadine alkaloids Rhoeadine alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Rhoeadine alkaloids

Comprehensive Analysis of 10,11-Methanediyldioxy-2,8beta-dimethoxy-(6alpha)-rheadan-3-ol (CAS No. 18104-24-0): Properties, Applications, and Research Insights

The compound 10,11-methanediyldioxy-2,8beta-dimethoxy-(6alpha)-rheadan-3-ol (CAS No. 18104-24-0) is a structurally unique molecule that has garnered attention in pharmaceutical and biochemical research. With its complex stereochemistry and functional groups, this compound serves as a valuable intermediate in the synthesis of bioactive derivatives. Researchers are increasingly exploring its potential in drug discovery and natural product synthesis, particularly due to its methanediyldioxy and dimethoxy moieties, which contribute to its stability and reactivity.

In recent years, the demand for specialty chemicals like 18104-24-0 has surged, driven by advancements in precision medicine and green chemistry. A growing number of studies focus on optimizing its synthesis to reduce environmental impact—a topic aligning with the global push for sustainable manufacturing. Questions such as "How is 10,11-methanediyldioxy-2,8beta-dimethoxy-(6alpha)-rheadan-3-ol synthesized?" or "What are its pharmacological applications?" frequently appear in scientific forums, reflecting its relevance in modern research.

The stereospecificity of this compound, particularly its 6alpha configuration, plays a critical role in its interactions with biological targets. Computational modeling studies suggest that its methanediyldioxy bridge enhances binding affinity to certain enzymes, making it a candidate for enzyme inhibition studies. This aligns with current trends in AI-driven drug design, where researchers leverage machine learning to predict molecular behavior.

From an industrial perspective, CAS No. 18104-24-0 is often discussed in the context of high-purity intermediates for APIs (Active Pharmaceutical Ingredients). Its stability under varying pH conditions makes it suitable for formulation development, a key concern for pharmaceutical companies aiming to improve drug delivery systems. Searches like "10,11-methanediyldioxy derivative solubility" or "scaling up rheadan-3-ol production" highlight practical challenges addressed in recent publications.

Environmental and regulatory considerations also shape the discourse around this compound. While not classified as hazardous, its synthesis often involves catalysts and solvents that require careful handling. The shift toward biocatalysis and flow chemistry offers promising alternatives to traditional methods, reducing waste and energy consumption—a priority for ESG-compliant laboratories.

In conclusion, 10,11-methanediyldioxy-2,8beta-dimethoxy-(6alpha)-rheadan-3-ol exemplifies the intersection of structural complexity and functional versatility. Its applications span from medicinal chemistry to material science, with ongoing research exploring novel derivatives. As the scientific community prioritizes efficient synthesis and targeted bioactivity, this compound remains a focal point for innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)